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Abstract
IMPORTANCE Previous trials on the effect of levothyroxine on depressive symptom scores in
patients with subclinical hypothyroidism were limited by small sample sizes (N = 57 to 94) and
potential biases.
OBJECTIVE To assess the effect of levothyroxine on the development of depressive symptoms in
older adults with subclinical hypothyroidism in the largest trial on this subject and to update a
previous meta-analysis including the results from this study.
DESIGN, SETTING, AND PARTICIPANTS This predefined ancillary study analyzed data from
participants in the Thyroid Hormone Replacement for Untreated Older Adults with Subclinical
Hypothyroidism (TRUST) trial, a double-blind, randomized, placebo-controlled, parallel-group clinical
trial conducted from April 2013 to October 31, 2016. The TRUST trial included adults aged 65 years
or older diagnosed with subclinical hypothyroidism, defined as the presence of persistently elevated
thyroid-stimulating hormone (TSH) levels (4.6-19.9 mIU/L) with free thyroxine (T4) within the
reference range. Participants were identified from clinical and general practitioner laboratory
databases and recruited from the community in Switzerland, the Netherlands, Ireland, and the UK.
This ancillary study included a subgroup of 472 participants from the Netherlands and Switzerland;
after exclusions, a total of 427 participants (211 randomized to levothyroxine and 216 to placebo)
were analyzed. This analysis was conducted from December 1, 2019, to September 1, 2020.
INTERVENTIONS Randomization to either levothyroxine or placebo.
MAIN OUTCOMES AND MEASURES Depressive symptom scores after 12 months measured with
the Geriatric Depression Scale (GDS-15), with higher scores indicating more depressive symptoms
(minimal clinically important difference = 2).
RESULTS A total of 427 participants with subclinical hypothyroidism (mean [SD] age, 74.52 [6.29]
years; 239 women [56%]) were included in this analysis. The mean (SD) TSH level was 6.57 (2.22)
mIU/L at baseline and decreased after 12 months to 3.83 (2.29) mIU/L in the levothyroxine group; in
the placebo group, it decreased from 6.55 (2.04) mIU/L to 5.91 (2.66) mIU/L. At baseline, the mean
(SD) GDS-15 score was 1.26 (1.85) in the levothyroxine group and 0.96 (1.58) in the placebo group.
The mean (SD) GDS-15 score at 12 months was 1.39 (2.13) in the levothyroxine and 1.07 (1.67) in the
placebo group with an adjusted between-group difference of 0.15 for levothyroxine vs placebo (95%
CI, −0.15 to 0.46; P = .33). In a subgroup analysis including participants with a GDS-15 of at least 2,
the adjusted between-group difference was 0.61 (95% CI, −0.32 to 1.53; P = .20). Results did not




treatment have an effect on the
development of depressive symptoms
in older adults with subclinical
hypothyroidism?
Findings In this ancillary study of a
randomized, placebo-controlled clinical
trial of 427 participants with subclinical
hypothyroidism, there was no
statistically significant difference in the
adjusted between-group difference in
the mean Geriatric Depression Score at
12 months between the levothyroxine
and placebo groups.
Meaning These results do not provide
evidence in favor of levothyroxine
therapy in older persons with subclinical
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Abstract (continued)
levothyroxine with depressive symptoms was updated to include these findings, resulting in an
overall standardized mean difference of 0.09 (95% CI, −0.05 to 0.22).
CONCLUSIONS AND RELEVANCE This ancillary study of a randomized clinical trial found that
depressive symptoms did not differ after levothyroxine therapy compared with placebo after 12
months; thus, these results do not provide evidence in favor of levothyroxine therapy in older
persons with subclinical hypothyroidism to reduce the risk of developing depressive symptoms.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01853579
JAMA Network Open. 2021;4(2):e2036645. doi:10.1001/jamanetworkopen.2020.36645
Introduction
Subclinical hypothyroidism is defined as elevated thyroid-stimulating hormone (TSH) levels in
combination with free thyroxine (T4) levels within the reference range.1 Subclinical hypothyroidism
is a frequent condition in the general population, in particular among women and older adults,2 with
a prevalence up to 10% to 15%.3,4 Increasing evidence suggests that patients with subclinical
hypothyroidism should not routinely be treated with levothyroxine.5-7 Current guidelines
recommend levothyroxine therapy for adults with TSH levels greater than 10 mIU/L and for people
with lower TSH values who are young, symptomatic, or have specific indications for prescribing.8,9
Levothyroxine has become the most prescribed drug in the US in 2014 and the second most
prescribed drug in the UK in 2019.10,11 More frequent testing or lower TSH thresholds could be
potential reasons for the increase in levothyroxine prescription.1
Among other indicators, depressive symptoms are a common reason for starting levothyroxine
therapy in patients with subclinical hypothyroidism.12 A recent meta-analysis of 4 trials on the effect
of levothyroxine therapy in adult patients with subclinical hypothyroidism found no benefit for
depressive symptoms,7 but data were limited by small sample sizes (N = 57-94) and potential biases,
such as risk of bias assessment and publication bias.7
The Thyroid Hormone Replacement for Untreated Older Adults with Subclinical
Hypothyroidism (TRUST) trial was a randomized, multicenter, double-blind placebo-controlled trial
on the benefits of levothyroxine for patients 65 years or older with subclinical hypothyroidism.6,13
Our study aimed, first, to assess the possible effect of levothyroxine therapy on depressive symptom
scores in older adults with subclinical hypothyroidism from the TRUST trial, and second, to update
the previous meta-analysis7 on the effect of levothyroxine therapy on depressive symptoms scores
including the results from the TRUST trial.6
Methods
This ancillary study is nested in a large, international study on levothyroxine therapy in older adults
with subclinical hypothyroidism (the TRUST trial), which was conducted from April 2013 to October
31, 2016.6,13 This ancillary study on depressive symptoms was predefined and registered in May 2013
separately from the main TRUST trial.14 In participants from 2 countries of the TRUST trial,
Switzerland and the Netherlands, depressive symptoms were measured at baseline and at 12-month
follow-up using the 15-item Geriatric Depression Scale (GDS-15). In a secondary analysis on incidence
of mild depression, participants from the TRUST site in Ireland were included. In Ireland, depressive
symptoms were measured by using the Center for Epidemiologic Studies Depression 20-item scale
(CESD-20). The protocol of the TRUST trial was accepted by the relevant ethics committees and was
published previously.13 Participants provided written consent to participate. The analysis plan for this
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ancillary study was accepted by the TRUST publication committee. This study followed the
Consolidated Standards of Reporting Trials (CONSORT) reporting guideline for clinical trials.15
The TRUST Trial
The main goal of the TRUST trial was to determine whether levothyroxine provides clinical benefits
in older persons with subclinical hypothyroidism.6 The TRUST trial protocol is available in
Supplement 1. In the TRUST trial, patients underwent randomization in a 1:1 ratio, with stratification
according to country, sex, and starting dose, with the use of randomly permuted blocks.6 The study
medication consisted of levothyroxine sodium tablets and matching placebo tablets taken orally
once daily. The active intervention started with levothyroxine at a dose of 50 μg daily (or 25 μg in
patients with a body weight of less than 50 kg or with known coronary heart disease, ie, previous
myocardial infarction or symptoms of angina pectoris), and the placebo group started with a
matching placebo for 6 to 8 weeks. The dose of levothyroxine was adjusted in 25-μg increments
based on TSH levels measured 6 to 8 weeks after starting the intervention, 6 to 8 weeks after each
dose adjustment, and at a 12-month follow-up in order to reach a TSH level within the reference
range (0.4-4.6 mIU/L) in the levothyroxine group. An identical schedule for adjusting the dosage of
placebo with mock titration was used to achieve an approximately equal frequency of dosage
adjustments between the groups to maintain blinding. The participants, investigators, and treating
physicians were unaware of the results of TSH measurements throughout the course of the trial and
remained blinded for treatment allocation.6
Participants
Potential participants aged 65 or older were identified from clinical and general practitioner
laboratory databases and recruited from the community in Switzerland, the Netherlands and Ireland.
Subclinical hypothyroidism was defined as the presence of persistently elevated TSH levels (4.6-
19.9 mIU/L) at a minimum of 2 occasions at least 3 months apart with free T4 within the reference
range. Participants were followed up for a minimum of 12 months. Exclusion criteria included the use
of levothyroxine, antithyroid medication, amiodarone, or lithium; recent hospitalization for major
illness; recent acute coronary syndrome, acute myocarditis, or pancreatitis; and terminal illness.
Depressive Symptoms
Depressive symptoms were measured using the 15-item Geriatric Depression Scale (GDS-15) at
baseline and 12-month follow-up. The GDS-15 is a well-validated test for depression screening in older
age, with validity to measure longitudinal changes.16-18 The GDS-15 score ranges from 0 to 15, with
higher scores indicating higher likelihood of depression. Score values from 0 to 2 indicate no
depressive symptoms; 3-5, mild depressive symptoms; and 6 or greater, severe depressive
symptoms.19 The minimal clinically important between-group difference on the GDS-15 is 2 points.18
In this study, we used the cutoff of 3, suggesting mild depression.18 One of the advantages of the
GDS-15 is that it relies less on the somatic symptoms of depression and has been proven valid for use
in patients with chronic physical diseases, as it is often the case in older adults.16 Visits with GDS-15
took place from April 2013 to May 2015 for the baseline assessment and from April 2014 to October
31, 2016, for the 12-month follow-up.
We defined the primary outcome as GDS-15 score at 12 months, adjusted for scores at baseline,
age, sex, country, and starting dose of levothyroxine. As a secondary analysis, we dichotomized the
depression scale using established cutoff values for depressive symptoms; for the GDS-15 score, a
cutoff score greater than 3 suggests mild depression.16 For this analysis, we additionally included
data from the TRUST site in Ireland, where depressive symptoms were measured using the CESD-20.
This is a self-rating scale that measures depressive symptoms during the past week. The scale ranges
from 0 to 60, with higher scores indicating more depressive symptoms. CESD-20 values from 16 to
20 indicate mild depressive symptoms, values from 20 to 25 indicate moderate symptoms, and
values of 25 and greater indicate severe depressive symptoms.20 In this study, we used the cutoff of
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20 to define the presence of depression.21 The CESD-20 has been shown to be a valid and reliable
instrument to measure depressive symptoms and has been widely used in older populations.22
Statistical Analysis
Analyses were conducted from December 1, 2019, to September 1, 2020. For the primary outcome
analysis, we performed a modified intention-to-treat analysis using those participants having
depressive symptoms outcomes (Figure 1). Using the available data set, we performed a power
calculation with 427 participants with a standard deviation of 2 and a mean GDS-15 score in control
of 1, which resulted in 100% power for detecting a mean difference of 2.0 points at a 1-sided α-level
of .05. We used a multivariable linear regression analysis to assess the mean difference and relative
95% CI in GDS-15 scores at the 12-month follow-up between the levothyroxine and placebo groups.
We adjusted the results for GDS-15 scores at baseline, age, sex, country, and starting dose of
levothyroxine.
In a secondary analysis, we first excluded participants with mild depression at baseline
(indicated by GDS-15 scores >3 or CESD-20 scores >20)16,23 and analyzed those who developed mild
depression during follow-up in both the levothyroxine and placebo groups. Second, we included
only participants with mild depression at baseline and analyzed those who recovered from mild
depression. We conducted both secondary analyses (1) only in participants from Switzerland and the
Netherlands and (2) including participants from Ireland (n = 87). We used a multivariable logistic
regression model to assess odds ratios (ORs) and 95% CIs adjusted for depressive symptoms scores
at baseline, age, sex, country, and starting dose of levothyroxine.
In subgroup analyses, we assessed the difference in GDS-15 scores at 12 months separately for
men and women, for participants above and below 75 years of age, for different TSH levels (4.5 to
<7.0, 7.0 to <10.0, and 10.0-20 mIU/L), and for participants with GDS-15 scores above and below 2, as
Figure 1. Flowchart of Study Participants
472 Randomized
A nested study within TRUST
on depressive symptoms
2647 Assessed for eligibility
1910 Excluded
1666 Not meeting inclusion criteria
1645
21
Had reversion of TSH 
level to <4.60 mlU/L
Other reasons
244 Declined to participate
737 Randomized
115 Irelanda 255 The Netherlands 217 Switzerland 150 UK


























211 Analyzed 216 Analyzed
In the Thyroid Hormone Replacement for Untreated
Older Adults with Subclinical Hypothyroidism (TRUST)
study sites in the Netherlands and Switzerland,
depressive symptoms were measured using the
Geriatric Depression Scale (GDS-15). TSH indicates
thyroid stimulating hormone.
a In 87 participants from Ireland, depressive
symptoms were measured using the Center for
Epidemiologic Studies Depression 20-item scale
(CESD-20); those participants were included in a
secondary analysis on incidence of mild depression.
In the UK, no depressive symptoms were measured.
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the minimal clinically relevant difference on the GDS-15 scale is 2 (first clinically relevant difference
from 0).18
We excluded participants without depressive symptom measurements (Figure 1). We used
ipsative imputation for participants with partially incomplete GDS-15 questionnaires,24 which means
we divided the number of positive answered questions by the number of not-missing questions and
multiplied this by 15 (amount of questions of the GDS-15 scale ÷ maximal score). This calculation is a
valid imputation method to impute data from the 15-item GDS scale if the percentage of its missing
items is 20% or less.24 From 427 participants (211 in treatment and 216 in the placebo group) with
available data on depressive symptoms, 4 participants had an incomplete GDS-15 questionnaire at
baseline, and 8 had an incomplete GDS-15 questionnaire at 12-month follow-up (only 1 participant
with more than 20% missing answers was included).
We conducted several sensitivity analyses to test the robustness of the results. In the main
analysis, we used a parametric model, because it has several advantages compared to nonparametric
models and because parametric models have been shown to perform statistically well if the study
size is big enough (n > 25).25 To verify, we also applied a nonparametric model (Kernel regression) in
a sensitivity analysis.26 In another sensitivity analysis, we excluded participants with antidepressant
treatment (Anatomical Therapeutic Chemical Classification System: N06A, n = 26). In a sensitivity
analysis, we imputed missing GDS-15 score at baseline or follow-up (n = 45). We imputed data under
the assumption of missing at random using multivariate regression imputation based on an
individual’s complete responses on the variables of sex, age, country, and starting dose of
levothyroxine. We additionally simulated a scenario assuming all missing GDS-15 scores at 12 months
to be 75% higher (imputed values multiplied by 1.75) and a worst-case scenario assuming all
participants with missing GDS-15 score in the placebo group to have a maximal score of 15 points at
12 months, whereas we assumed that participants with missing scores in the treatment group had a
score of 0 at 12 months.
Update of Meta-analysis
As this study is, to our knowledge, the biggest trial to investigate the effect of levothyroxine on
depressive symptoms in patients with subclinical hypothyroidism, we also updated a recent meta-
analysis on 278 participants with the results from this ancillary study on the TRUST trial on 427
participants.7 Because studies used different scores to assess depressive symptoms, we pooled
standardized mean differences (SMDs) using a random effects model. A negative SMD indicates
benefit of levothyroxine therapy, with −0.2, −0.5, and −0.8 corresponding to small, moderate, and
large effects, respectively.27 Heterogeneity was assessed with I2 statistics (might not be important:
0%-40%; moderate: 30%-60%; substantial: 50%-90%; considerable: >75%).27 Two reviewers
(L.W. and M.F.) independently evaluated the quality of evidence using the Grading of
Recommendations, Assessment, Development and Evaluation (GRADE) tool.28 The certainty of
evidence reflects the extent to which the confidence in the estimate of the effect is adequate to
support a recommendation regarding levothyroxine therapy in participants with subclinical
hypothyroidism and depressive symptoms.
In a sensitivity analysis, we excluded studies that were only conducted in elderly participants
from the meta-analysis.
All analyses were conducted with STATA version 16 (StataCorp LLC) for Windows.
Results
A total of 427 participants were included in the main analysis (mean age [SD] age, 74.52 (6.29) years;
239 women [56.0%]) (Table 1). The mean (SD) TSH level was 6.57 (2.22) mIU/L at baseline and
decreased after 12 months to 3.83 (2.29) mIU/L in the levothyroxine group; in the placebo group, it
decreased from 6.55 (2.04) mIU/L to 5.91 (2.66) mIU/L. At baseline, the mean (SD) GDS-15 score was
1.26 (1.85) in the levothyroxine group and 0.96 (1.58) in the placebo group. The mean (SD) GDS-15
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score at 12 months was 1.39 (2.13) for levothyroxine group and 1.07 (1.67) for the placebo group with
an adjusted between-group difference of 0.15 (95% CI, −0.15 to 0.46; P = .33; minimal clinically
relevant difference = 2.0)18 (Table 2).
Of the 472 participants from the Netherlands and from Switzerland, 236 were allocated to
levothyroxine and 236 to the placebo group (Figure 1). Forty-five participants were excluded from
the analysis (5 participants died before the 12-month visit, 6 had a missing GDS-15 score at baseline or
the 12-month visit, 20 missed the 12-month visit, and 14 withdrew before the 12-month visit). The
proportion of excluded participants was similar in the 2 groups (25 participants [11%] in the
treatment group and 20 [8%] in the placebo group). Participants who were lost to follow-up (n = 34)
had a higher mean (SD) GDS-15 score (1.80 [2.42]) at baseline compared with those with a completed
follow-up (1.11 [1.72]). Finally, 427 participants were included in the main analysis of this ancillary
study, with 211 receiving levothyroxine and 216 receiving the placebo. The baseline characteristics of
the 45 excluded participants were similar to those who were included (eTable 1 in Supplement 2).
There was no clinically relevant difference in depressive symptoms at 12 months in subgroup
analyses by age, sex, and TSH levels (Figure 2), nor in participants with GDS-15 scores of 2 or higher
at baseline (adjusted between-group difference, 0.61; 95% CI, −0.32 to 1.53; P = .20).
In a secondary analysis, we calculated the incidence of mild depression. At baseline, 188
patients in the levothyroxine group and 206 in the placebo group had no mild depression . During
Table 1. Characteristics of Participants at Baseline
Characteristic
No. (%)
Levothyroxine (n = 211) Placebo (n = 216)
Age, mean (range), y 73.99 (65.37-91.17) 75.04 (65.12-93.40)
Women 118 (56) 121 (56)
Previous medical conditions and clinical descriptors
Atrial fibrillation 28 (13) 23 (11)
Hypertension 102 (48) 98 (46)
Diabetes 34 (16) 26 (12)
Osteoporosis 26 (13) 31 (15)
Current smoking 18 (9) 19 (9)
Dementia 0 0
Excess alcohol consumptiona 2 (1) 3 (1)
Antidepressants medication 16 (8) 10 (5)
Mini-Mental State Examination score, mean (SD) 28.52 (1.39) 28.68 (1.42)
Weight
Mean (range), kg 77.58 (46-150) 76.76 (44-121)
<50 kg 4 (2) 3 (1)
BMI, mean (SD) 27.88 (5.54) 27.60 (4.37)
TSH, mean (SD) [range], mIU/L 6.57 (2.22) [4.60-17.58] 6.55 (2.04) [4.60-17.60]
Free T4, mean (SD) [range], pmol/L 13.69 (1.97) [10.00-20.60] 13.61 (1.86) [9.00-21.90]
GDS-15 score, mean (SD) [range] 1.26 (1.85) [0-9] 0.96 (1.58) [0-12]
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); GDS-15, 15-item Geriatric Depression Scale
Questionnaire (range, 0-15; higher scores indicate
more severe depressive symptoms; minimal clinically
important difference, 2 points); TSH, thyroid
stimulating hormone; T4, thyroxine.
a More than 35 units per week for women and more
than 50 units per week for men.
Table 2. Difference in GDS-15 Score at 12 Months Between Levothyroxine and Placebo Groups
Mean (SD) GDS-15 score
Unadjusted mean
difference at 12 mo
(95% CI)a P value
Mean difference at 12
mo, djusted for age
and sex (95% CI)a P value
Fully adjusted mean
difference at 12 mo










1.26 (1.85) 0.96 (1.58) 1.39 (2.13) 1.07 (1.67) 0.32 (−0.05 to 0.68) .09 0.35 (−0.02 to 0.71) .06 0.15 (−0.15 to 0.46) .33
Abbreviations: GDS-15, 15-item Geriatric Depression Scale Questionnaire (range, 0-15;
higher scores indicate more severe depressive symptoms; minimal clinically important
difference, 2 points).
a Positive results indicate benefit of placebo.
b Adjusted for age, sex, GDS-15 score at baseline, levothyroxine dose at baseline,
and country.
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follow-up, 10 participants from the levothyroxine group (5.3%) and 12 participants from the placebo
group (5.8%) developed mild depression (GDS-15 score >3). The OR for mild depression comparing
the levothyroxine group vs the placebo group was 0.87 (95% CI, 0.36-2.13). We then repeated the
analysis after adding 87 participants from Ireland with available data on CESD-20 scores, for an OR of
1.06 (95% CI, 0.45-2.49; values >1 indicate benefit of levothyroxine therapy) (eTable 2 in
Supplement 2). When we only included participants with mild depression at baseline, the OR for
recovery of mild depression was 0.20 (95% CI, 0.02-1.93; values <1 indicate benefit of placebo)
(eTable 3 in Supplement 2).
Results stayed robust in a sensitivity analysis excluding participants with antidepressant
medication at baseline (adjusted between-group difference, 0.14; 95% CI, −0.17 to 0.46) or using the
Kernel-regression model (adjusted between-group difference, 0.12; 95% CI, −0.38 to 0.41). The
results stayed robust when we imputed missing GDS-15 scores at baseline and follow-up and when
we simulated missing values assuming the missing values to be 75% higher than nonmissing values.
When we simulated a worst-case scenario for missing values at 12 months, the difference between
the groups was below minimal clinically important difference (−1.17; 95% CI, −1.74 to −0.61).
To pool the results from this ancillary study on depressive symptoms within the TRUST trial to
the previous meta-analysis,7 we transformed the adjusted mean difference in depressive symptoms
between the 2 groups of 0.15 (95% CI, −0.15 to 0.46) to an adjusted standardized mean difference
(SMD) of 0.08 (95% CI, −0.08 to 0.24). When we pooled the adjusted SMD with the previous
meta-analysis,7 we found an overall SMD of 0.09 (95% CI, −0.05 to 0.22) (Figure 3). There was no
statistical heterogeneity (I2 = 0.0%). In a sensitivity analysis including only 3 studies that were not
only conducted in elderly participants, we found an overall SMD of 0.09 (95% CI, −0.20 to 0.38).29-31
This ancillary study on depression within a randomized controlled trial had a weight of 67.6% to the
overall effect. The quality of evidence assessed with the GRADE tool was high, indicating that further
research is very unlikely to change our confidence in the estimate of effect (eTable 4 in
Supplement 2).
Discussion
In this ancillary study within a randomized controlled trial among adults aged 65 years or older with
subclinical hypothyroidism, levothyroxine therapy for 12 months had no clinical effect on depressive
Figure 2. Subgroup Analyses: Difference in GDS-15 Score at 12 Months Between Levothyroxine
and Placebo Groups
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JAMA Network Open | Diabetes and Endocrinology Effect of Levothyroxine on Depressive Symptoms in Older Adults With Subclinical Hypothyroidism
JAMA Network Open. 2021;4(2):e2036645. doi:10.1001/jamanetworkopen.2020.36645 (Reprinted) February 10, 2021 7/12
Downloaded From: https://jamanetwork.com/ by a Universitaetsbibliothek Bern User  on 02/11/2021
symptom scores. Nor was there a difference in the incidence of mild depression in the levothyroxine
group compared with the placebo group after 12 months. The results stayed robust in several
subgroup analyses. In this study, we additionally found that participants with slightly increased
depression scores at baseline (GDS-15  2) did not improve under levothyroxine therapy compared
with placebo.
Observational studies on the association between subclinical hypothyroidism and depressive
symptoms have yielded conflicting results. Several studies showed that participants with subclinical
hypothyroidism had more severe depressive symptoms, but other studies reported no
differences.32-38 However, our recently conducted individual participant data (IPD) analysis,
including younger and older participants, revealed no prospective association between subclinical
hypothyroidism and depressive symptoms.39 Previous clinical trials were rather small and could not
find an effect of levothyroxine therapy on depressive symptoms.29-31,40
Strengths and Limitations
This study has several strengths. First, the large sample size makes it the largest trial, to our
knowledge, on depressive symptoms in patients with subclinical hypothyroidism. Second, we
updated the previous meta-analysis to include this study. The effect estimate’s confidence interval
excluded a possible effect of levothyroxine on the development of depressive symptoms in
participants with subclinical hypothyroidism. Third, the quality of evidence assessed with the GRADE
scale was high, which indicates that further research is very unlikely to change our confidence in the
estimate of effect.28
This study has some limitations. First, GDS-15 scores were low in our study population at
baseline as reflected in the general population. Therefore, we cannot exclude that patients with
subclinical hypothyroidism and moderate or severe depressive symptoms might benefit from
levothyroxine therapy. Second, participants lost to follow-up had a higher mean GDS-15 score at
baseline compared to those with a completed follow-up, which suggests that participants with higher
scores were more likely lost to follow-up. In a sensitivity analysis in which we imputed missing scores,
assuming participants with missing scores to have 75% higher scores, results stayed robust. Third,
as we only included participants aged 65 years or older, our results are not generalizable to younger
patients with subclinical hypothyroidism. Fourth, this study on depressive symptoms was an ancillary
study of the TRUST trial; therefore, we were not able to include all participants from the original
study, as depressive symptoms were not measured at all sites of the TRUST trial. Fifth, depressive
symptoms were self-reported.
Figure 3. Update of Meta-analysis: Standardized Mean Differences Between Levothyroxine and Placebo Groups in Depressive Symptoms
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Weights are derived from a random-effects meta-analysis of standardized mean
differences. Standardized mean differences of −0.2, −0.5, and −0.8 correspond to small,
moderate, and large clinical positive effects of levothyroxine, respectively. The size of
the boxes indicates the study weight in the meta-analysis, the whiskers represent 95%
CIs, the diamond shows the result of the meta-analysis, and the vertical dashed line
represents the point estimate of the pooled standardized mean difference. HADS
indicates Hospital Anxiety and Depression Scale; TRUST, Thyroid Hormone Replacement
for Untreated Older Adults With Subclinical Hypothyroidism.
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Conclusion
Current guidelines on subclinical hypothyroidism recommend taking into account age, TSH levels,
and the presence of related symptoms when deciding whether to treat a patient with subclinical
hypothyroidism with levothyroxine.5,9,41 This ancillary study of a randomized clinical trial found no
effect of levothyroxine therapy on the development of depressive symptoms in older patients, even
among those with a TSH level higher than 10 mIU/L, although this group was relatively small. Findings
from this study do reinforce the current recommendation that levothyroxine therapy should not be
prescribed to reduce the risk of depressive symptoms in adults with subclinical hypothyroidism, with
high quality of evidence.5 However, uncertainty remains on the effect of the treatment among
severely depressed patients, as this trial was only conducted in patients with rather low depressive
symptom scores at baseline.
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